JP2022183183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022183183A5 JP2022183183A5 JP2022152791A JP2022152791A JP2022183183A5 JP 2022183183 A5 JP2022183183 A5 JP 2022183183A5 JP 2022152791 A JP2022152791 A JP 2022152791A JP 2022152791 A JP2022152791 A JP 2022152791A JP 2022183183 A5 JP2022183183 A5 JP 2022183183A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- composition
- vegf
- patient
- wamd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/093548 | 2014-12-11 | ||
| PCT/CN2014/093548 WO2016090590A1 (en) | 2014-12-11 | 2014-12-11 | Treatment of age related macular degeneration with a small active choroidalneovascularizationlesion |
| CNPCT/CN2015/089251 | 2015-09-09 | ||
| CN2015089251 | 2015-09-09 | ||
| JP2020173951A JP2021004262A (ja) | 2014-12-11 | 2020-10-15 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020173951A Division JP2021004262A (ja) | 2014-12-11 | 2020-10-15 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022183183A JP2022183183A (ja) | 2022-12-08 |
| JP2022183183A5 true JP2022183183A5 (https=) | 2023-09-27 |
Family
ID=55069121
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530277A Active JP7320919B2 (ja) | 2014-12-11 | 2015-12-10 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 |
| JP2020173951A Pending JP2021004262A (ja) | 2014-12-11 | 2020-10-15 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 |
| JP2022152791A Pending JP2022183183A (ja) | 2014-12-11 | 2022-09-26 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530277A Active JP7320919B2 (ja) | 2014-12-11 | 2015-12-10 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 |
| JP2020173951A Pending JP2021004262A (ja) | 2014-12-11 | 2020-10-15 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20170326106A1 (https=) |
| EP (2) | EP3985023A1 (https=) |
| JP (3) | JP7320919B2 (https=) |
| CN (3) | CN114306575A (https=) |
| AU (4) | AU2015360496B2 (https=) |
| CA (1) | CA2970315C (https=) |
| DK (1) | DK3230316T3 (https=) |
| ES (1) | ES2907148T3 (https=) |
| HR (1) | HRP20220066T1 (https=) |
| HU (1) | HUE057653T2 (https=) |
| LT (1) | LT3230316T (https=) |
| PL (1) | PL3230316T3 (https=) |
| PT (1) | PT3230316T (https=) |
| RS (1) | RS62827B1 (https=) |
| SI (1) | SI3230316T1 (https=) |
| WO (1) | WO2016094673A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2494108C2 (ru) | 2006-04-07 | 2013-09-27 | Аерпио Терапетикс, Инк. | Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование |
| WO2013056240A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CN114306575A (zh) | 2014-12-11 | 2022-04-12 | 拜耳医药保健有限责任公司 | 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗 |
| US10525035B2 (en) * | 2014-12-18 | 2020-01-07 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of retinopathy and other ocular diseases |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| SG11202006712XA (en) * | 2018-02-06 | 2020-08-28 | Hoffmann La Roche | Treatment of ophthalmologic diseases |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| WO2020068653A1 (en) | 2018-09-24 | 2020-04-02 | Aerpio Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF |
| MY195550A (en) | 2018-10-29 | 2023-01-31 | Hoffmann La Roche | Antibody Formulation |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US11944663B2 (en) * | 2020-06-18 | 2024-04-02 | Chengdu Kanghong Biotechnologies Co. Ltd. | Method for treating angiogenic eye disorders using VEGF antagonists |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| JP2025036369A (ja) * | 2023-08-31 | 2025-03-14 | 国立大学法人京都大学 | 光感受性物質含有リポタンパク質、光線力学的療法用製剤、薬物デリバリー方法及び後眼部新生血管閉塞方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2177950C2 (ru) | 1996-10-25 | 2002-01-10 | Нексстар Фармасьютикалз, Инк. | Комплексы нуклеиновых кислот - лигандов сосудистого эндотелиального фактора роста (vegf) |
| KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| CN101433715B (zh) | 1999-06-08 | 2013-04-17 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| CA2437563C (en) * | 2001-02-06 | 2010-03-23 | Qlt Inc. | Photodynamic therapy of occult age-related macular degeneration |
| CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| KR20190049934A (ko) * | 2011-01-13 | 2019-05-09 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| CN114306575A (zh) | 2014-12-11 | 2022-04-12 | 拜耳医药保健有限责任公司 | 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗 |
-
2015
- 2015-12-10 CN CN202210019267.XA patent/CN114306575A/zh active Pending
- 2015-12-10 CA CA2970315A patent/CA2970315C/en active Active
- 2015-12-10 HR HRP20220066TT patent/HRP20220066T1/hr unknown
- 2015-12-10 AU AU2015360496A patent/AU2015360496B2/en active Active
- 2015-12-10 PL PL15819965T patent/PL3230316T3/pl unknown
- 2015-12-10 CN CN201580066980.8A patent/CN106999511A/zh active Pending
- 2015-12-10 EP EP21207057.7A patent/EP3985023A1/en active Pending
- 2015-12-10 DK DK15819965.3T patent/DK3230316T3/da active
- 2015-12-10 PT PT158199653T patent/PT3230316T/pt unknown
- 2015-12-10 RS RS20220058A patent/RS62827B1/sr unknown
- 2015-12-10 ES ES15819965T patent/ES2907148T3/es active Active
- 2015-12-10 SI SI201531805T patent/SI3230316T1/sl unknown
- 2015-12-10 JP JP2017530277A patent/JP7320919B2/ja active Active
- 2015-12-10 HU HUE15819965A patent/HUE057653T2/hu unknown
- 2015-12-10 LT LTEPPCT/US2015/065022T patent/LT3230316T/lt unknown
- 2015-12-10 WO PCT/US2015/065022 patent/WO2016094673A1/en not_active Ceased
- 2015-12-10 EP EP15819965.3A patent/EP3230316B1/en active Active
- 2015-12-10 CN CN202110181096.6A patent/CN112826934A/zh active Pending
- 2015-12-10 US US15/534,030 patent/US20170326106A1/en not_active Abandoned
-
2019
- 2019-06-26 US US16/453,242 patent/US20190381008A1/en active Pending
-
2020
- 2020-10-15 JP JP2020173951A patent/JP2021004262A/ja active Pending
-
2021
- 2021-10-08 AU AU2021107575A patent/AU2021107575A4/en not_active Expired
- 2021-10-08 AU AU2021245214A patent/AU2021245214B2/en active Active
-
2022
- 2022-09-26 JP JP2022152791A patent/JP2022183183A/ja active Pending
-
2024
- 2024-07-31 AU AU2024205237A patent/AU2024205237A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022183183A5 (https=) | ||
| AU2021245214B2 (en) | Treatment of age related macular degeneration with a small active choroidal neovascularization lesion | |
| Brown et al. | Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration–primary end point | |
| JP2025169389A5 (https=) | ||
| Faghihi et al. | Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema | |
| Cukras et al. | Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study | |
| JP2017061467A5 (https=) | ||
| CN1582156A (zh) | 眼新血管疾病的治疗方法 | |
| CA3025258C (en) | Use of sirolimus to treat exudative age-related macular degeneration with persistent edema | |
| JP5934229B2 (ja) | 眼血管疾患の処置のための投与計画 | |
| JP7828274B2 (ja) | 眼疾患を治療するための方法 | |
| Kang et al. | The efficacy of ranibizumab for choroidal neovascularization in age-related macular degeneration | |
| CN105263574A (zh) | 息肉状脉络膜血管病变的治疗 | |
| Querques et al. | Intravitreal ranibizumab for choroidal neovascularization associated with retinal astrocytic hamartoma | |
| HK40071471A (en) | Treatment of age related macular degeneration with a small active choroidal neovascularization lesion | |
| HK40051590A (en) | Treatment of age related macular degeneration with a small active choroidal neovascularization lesion | |
| Bennet | Pegaptanib for the treatment of ischemic retinopathy in patients with diabetes and retinal vascular occlusive disorders | |
| TW202525324A (zh) | 治療年齡相關性黃斑變性和糖尿病性黃斑水腫的方法 | |
| Sinha et al. | Anti-vascular endothelial growth factor in ophthalmology | |
| WO2024153184A1 (zh) | 一种使用抗vegf抗体治疗眼底血管病变的方法 | |
| Mahar et al. | Visual Outcome Following Intra-vitreal Bevacizumab Injection in Neovascular Age-related Macular Degeneration | |
| Wong et al. | Vitreous, Choroid, and Retina | |
| OPTHALMOLOGY | A MULTIVARIATE ANALYSIS OF INTRA VITREAL INJECTION OF ANTI VEGF BEVACIZUMAB IN THE TREATMENT OF RETINAL AND CHOROIDAL NEOVASCULARISATION | |
| WO2016090590A1 (en) | Treatment of age related macular degeneration with a small active choroidalneovascularizationlesion | |
| Sivaprasad | S Jyothi, HR Chowdhury, V Chong and |